DP-Allopurinol

দেশ: নিউ জিলণ্ড

ভাষা: ইংরেজি

সূত্র: Medsafe (Medicines Safety Authority)

সক্রিয় উপাদান:

Allopurinol 300mg

থেকে পাওয়া:

Douglas Pharmaceuticals Limited

INN (আন্তর্জাতিক নাম):

Allopurinol 300 mg

ডোজ:

300 mg

ফার্মাসিউটিকাল ফর্ম:

Tablet

রচনা:

Active: Allopurinol 300mg Excipient: Lactose monohydrate Magnesium stearate Maize starch Povidone

প্রেসক্রিপশন টাইপ:

Prescription

Manufactured by:

Indoco Remedies Limited

থেরাপিউটিক ইঙ্গিত:

· Allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. It is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. If changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. In severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

পণ্য সারাংশ:

Package - Contents - Shelf Life: Blister pack, Clear PVC/Plain aluminium - 28 dose units - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Blister pack, Clear PVC/Plain aluminium - 56 dose units - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Bottle, plastic, White HDPE with non-CRC cap - 100 dose units - 24 months from date of manufacture stored at or below 25°C protect from light and moisture - Bottle, plastic, White HDPE with non-CRC cap - 500 dose units - 24 months from date of manufacture stored at or below 25°C protect from light and moisture

অনুমোদন তারিখ:

2015-06-25

পণ্য বৈশিষ্ট্য

NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
DP-Allopurinol 100 mg and 300 mg Tablets
2.
QUALITATIVE AND QUATITATIVE COMPOSITION
Allopurinol 100 mg
Allopurinol 300 mg
Allopurinol tablets contain lactose. For the full list of excipients,
see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Each 100 mg tablet is white to off-white, scored, flat cylindrical
tablet debossed with ‘I’
and ‘56’ on either side of the break line on one side and plain on
other side.
Each 300 mg tablet is white to off-white, scored, flat cylindrical
tablet debossed with ‘I’
and ‘57’ on either side of the break line on one side and plain on
other side.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
DP-Allopurinol
is
mainly
used
in
the
management
of
primary
gout
or
secondary
hyperuricaemia associated with chronic gout. It is not, however, used
to treat an acute
attack of gout as it has no analgesic, anti-inflammatory or uricosuric
activity and may
prolong the attack. If changing therapy from a uricosuric agent alone,
the dose should be
reduced gradually while allopurinol is introduced. In severe cases of
chronic gout,
allopurinol can be used together with a uricosuric agent unless the
latter is contra-
indicated.
It is indicated for reducing urate/uric acid formation in conditions
where urate/uric acid
deposition may occur such as: uric acid nephropathy; recurrent uric
acid stone formation;
certain enzyme disorders or blood disorders which lead to
overproduction of urate (e.g.
Lesch-Nyhan
syndrome;
haemolytic
anaemia);
hyperuricaemia
associated
with
malignancy and cytotoxic therapy which result in a high cell turnover
rate.
DP-Allopurinol
is
indicated
for
the
prevention
and
treatment
of
calcium
oxalate/phosphate renal stones in the presence of high uric acid
levels of the blood and/or
urine.
4.2.
DOSE AND METHOD OF ADMINISTRATION
Dose
DP-Allopurinol may increase the frequency of acute attacks during the
first few months
of therapy; it is therefore recommended that low doses be given
initi